Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Genotype, oxidase status, and preceding infection or autoinflammation do not affect allogeneic HCT outcomes for CGD

Jennifer W. Leiding, Danielle E. Arnold, Suhag Parikh, Brent Logan, Rebecca A. Marsh, Linda M. Griffith, Ruizhe Wu, Sharon Kidd, Kanwaldeep Mallhi, Deepak Chellapandian, Stephanie J. Si Lim, Eyal Grunebaum, E. Liana Falcone, Luis Murguia-Favela, Debbi Grossman, Vinod K. Prasad, Jennifer R. Heimall, Fabien Touzot, Lauri M. Burroughs, Jack Bleesing, Neena Kapoor, Jasmeen Dara, Olatundun Williams, Malika Kapadia, Benjamin R. Oshrine, Jeffrey J. Bednarski, Ahmad Rayes, Hey Chong, Geoffrey D. E. Cuvelier, Lisa R. Forbes Satter, Caridad Martinez, Mark T. Vander Lugt, Lolie C. Yu, Shanmuganathan Chandrakasan, Avni Joshi, Susan E. Prockop, Blachy J. Dávila Saldaña, Victor Aquino, Larisa A. Broglie, Christen L. Ebens, Lisa M. Madden, Kenneth DeSantes, Jordan Milner, Hemalatha G. Rangarajan, Ami J. Shah, Alfred P. Gillio, Alan P. Knutsen, Holly K. Miller, Theodore B. Moore, Pamela Graham, Andrea Bauchat, Nancy J. Bunin, Pierre Teira, Aleksandra Petrovic, Sharat Chandra, Hisham Abdel-Azim, Morna J. Dorsey, Olga Birbrayer, Morton J. Cowan, Christopher C. Dvorak, Elie Haddad, Donald B. Kohn, Luigi D. Notarangelo, Sung-Yun Pai, Jennifer M. Puck, Michael A. Pulsipher, Troy R. Torgerson, Harry L. Malech, Elizabeth M. Kang

Blood (2023) 142 (24): 2105–2118.

https://doi.org/10.1182/blood.2022019586

Published: 2023

Includes: Supplemental data

Journal Articles

Impact of Public Reporting of Center-Specific Analysis Scores on Hematopoietic Cell Transplant Center Volumes

Akshay Sharma, Brent Logan, Noel Estrada-Merly, Leslie E. Lehmann, Hemalatha G. Rangarajan, Jaime M. Preussler, Jesse D. Troy, Luke P. Akard, Neel S. Bhatt, Tony H. Truong, William A. Wood, Jr., Douglas Rizzo, Wael Saber

Blood (2022) 140 (Supplement 1): 10845–10846.

https://doi.org/10.1182/blood-2022-163451

Published: 2022

Journal Articles

Development of a Validated Clinical Risk Score to Predict the Incidence of Acute Graft Versus Host Disease after Allogeneic Hematopoietic Cell Transplantation: A CIBMTR Analysis

Caden Ulschmid, Xiao Li, Tao Wang, Brent Logan, Joseph Pidala, Margaret L. MacMillan, Carrie Lynn Kitko, Stephanie J. Lee, Stephen R. Spellman, Wael Saber

Blood (2022) 140 (Supplement 1): 279–281.

https://doi.org/10.1182/blood-2022-163263

Published: 2022

Journal Articles

Access: A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Patients with Hematologic Malignancies

Monzr M. Al Malki, Steven M Devine, Bronwen E. Shaw, Larisa Broglie, Muna Qayed, Sung W. Choi, Stephen R. Spellman, Craig Malmberg, Eric Ndifon, Brent Logan, Jeffery Auletta, Heather E Stefanski, Janelle A. Olson, Antonio Jimenez Jimenez

Blood (2022) 140 (Supplement 1): 7591–7593.

https://doi.org/10.1182/blood-2022-162581

Published: 2022

Journal Articles

Quality of Life in Patients Undergoing Double Umbilical Cord Blood Vs. Haploidentical Marrow Transplantation: A QOL Analysis Report of BMT CTN 1101

Najla El Jurdi, Michael Martens, Claudio G. Brunstein, Paul O'Donnell, Stephanie J. Lee, Anita D'Souza, Brent Logan, Sanghee Hong, Karam Sandhu, Roman M Shapiro, Anurag K. Singh, Mary M. Horowitz, Betty K. Hamilton

Blood (2022) 140 (Supplement 1): 10545–10546.

https://doi.org/10.1182/blood-2022-158828

Published: 2022

Journal Articles

Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial

Ephraim J. Fuchs, Paul V. O’Donnell, Mary Eapen, Brent Logan, Joseph H. Antin, Peter Dawson, Steven Devine, Mary M. Horowitz, Mitchell E. Horwitz, Chatchada Karanes, Eric Leifer, John M. Magenau, Joseph P. McGuirk, Lawrence E. Morris, Andrew R. Rezvani, Richard J. Jones, Claudio G. Brunstein

Blood (2021) 137 (3): 420–428.

https://doi.org/10.1182/blood.2020007535

Published: 2021

Includes: Supplemental data

Journal Articles

Impact of Cryopreservation of Donor Grafts on Outcomes of Allogeneic Hematopoietic Cell Transplant (HCT)

Jack W. Hsu, MD, Nosha Farhadfar, MD, Hemant S. Murthy, MD, Brent Logan, PhD, Stephanie Bo-Subait, MPH, Noelle V. Frey, MD, Steven C. Goldstein, MD, Mary M. Horowitz, MD MS, Hillard M Lazarus, MD, Joshua Schwanke, Nirali N. Shah, MD, Stephen R. Spellman, MS, Galen E. Switzer, PhD, Steven M Devine, MD, Bronwen E. Shaw, PhD MRCP, FRCPath, John R. Wingard, MD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-136778

Published: 2020

Journal Articles

BMT CTN 1803: Haploidentical Natural Killer Cells (K-NK002) to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)

Sumithra Vasu, MDMBBS, Nelli Bejanyan, MD, Steven M Devine, MD, Elizabeth O. Hexner, MD MSTR, Brent Logan, PhD, Leo Luznik, MD, Brittany K. Ragon, MD, Andrew Sandler, MD, Elizabeth F Krakow, MDMSc, Michael Fitzgerald, Lorraine Tracey, PhD, Richard E. Champlin, MD

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-134408

Published: 2020

Journal Articles

Expanded Comorbidity Definitions Improve Applicability of the Hematopoietic Stem Cell Transplantation-Comorbidity Index for Children, Adolescents, and Young Adults with Hematologic Malignancies Undergoing Allogeneic Stem Cell Transplantation

Brian D Friend, MD, Larisa Broglie, MD MS, Brent Logan, PhD, Caitrin Fretham, MPH, Gary J. Schiller, MD, Bipin N. Savani, MD, Edward Stadtmauer, Saurabh Chhabra, MD, Marcelo C. Pasquini, MDMS, Monica Thakar, MD, Mohamed Sorror, MD MSc

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-140778

Published: 2020

Journal Articles

Bridging the Gap in Access to Transplant for Underserved Minority Patients Using Mismatched Unrelated Donors and Post-Transplant Cyclophosphamide: A National Marrow Donor Program/be the Match (NMDP/BTM) Initiative

Blood (2020) 136 (Supplement 1): 48–49.

https://doi.org/10.1182/blood-2020-137677

Published: 2020

Journal Articles

Expanded Comorbidity Definitions Improve Application of the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) for Children and Young Adults with Non-Malignant Diseases Receiving Allogeneic Hematopoietic Cell Transplantation

Larisa Broglie, MD MS, Brian D Friend, MD, Brent Logan, PhD, Caitrin Fretham, MPH, Gary J. Schiller, MD, Bipin N. Savani, MD, Edward A. Stadtmauer, MD FACP, Saurabh Chhabra, MD, Marcelo C. Pasquini, MDMS, Monica Thakar, MD, Mohamed Sorror, MD MSc

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-140637

Published: 2020

Journal Articles

Non-Infectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell Transplantation (HCT): A Center for International Blood and Marrow Transplant Research (CIBMTR) Study

Sagar S. Patel, MD, Kwang Woo Ahn, PhD, Manoj Khanal, BS, MS, Caitrin Fretham, MPH, Celalettin Ustun, MD, Betty K. Hamilton, MD, Navneet S. Majhail, MD MS, Shin Mineishi, MD, Bipin N. Savani, MD, Mohamed Sorror, MD MSc, Edward A. Stadtmauer, MD FACP, Brent Logan, PhD, Marcelo C. Pasquini, MDMS, Saurabh Chhabra, MD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-140503

Published: 2020

Journal Articles

A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplantation to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network Study 1102

Blood (2020) 136 (Supplement 1): 19–21.

https://doi.org/10.1182/blood-2020-136828

Published: 2020

Journal Articles

BMT CTN 1803: Haploidentical Natural Killer Cells (CSTD002) to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)

Sumithira Vasu, MDMBBS, Nelli Bejanyan, MD, Steven Devine, MD, Elizabeth Krakow, MDMSc, Elizabeth Krakow, MD, Brent Logan, PhD, Leo Luznik, MD, Brittany K Ragon, MD, Emma Barrett, MD, Joe Shan, MPH, BS, Richard E. Champlin, MD

Blood (2019) 134 (Supplement_1): 1955.

https://doi.org/10.1182/blood-2019-128005

Published: 2019

Journal Articles

The Hematopoietic Cell Transplant Comorbidity Index predicts survival after allogeneic transplant for nonmalignant diseases

Monica S. Thakar, Larisa Broglie, Brent Logan, Andrew Artz, Nancy Bunin, Lauri M. Burroughs, Caitrin Fretham, David A. Jacobsohn, Alison W. Loren, Joanne Kurtzberg, Caridad A. Martinez, Shin Mineishi, Adam S. Nelson, Ann Woolfrey, Marcelo C. Pasquini, Mohamed L. Sorror

Blood (2019) 133 (7): 754–762.

https://doi.org/10.1182/blood-2018-09-876284

Published: 2019

Includes: Supplemental data

Journal Articles

Pain, Symptoms, AEs, and Recovery after Second Unrelated Donor Collection of Marrow/Peripheral Blood Stem Cells Are Similar to Those of the First Donation

David Stroncek, MD, Bronwen E. Shaw, MBChB, PhD MRCP, MRCPath, Brent Logan, PhD, Deidre Marie Kiefer, MPH, Pintip Chitphakdithai, PhD, Galen E. Switzer, PhD, Nirali N Shah, MD, John P. Miller, MD PhD, Dennis L. Confer, MD, Michael A Pulsipher, MD

Blood (2016) 128 (22): 2177.

https://doi.org/10.1182/blood.V128.22.2177.2177

Published: 2016

Journal Articles

Blockade of interleukin-27 signaling reduces GVHD in mice by augmenting Treg reconstitution and stabilizing Foxp3 expression

Ludovic Belle, Kimberle Agle, Vivian Zhou, Cheng Yin-Yuan, Richard Komorowski, Daniel Eastwood, Brent Logan, Jie Sun, Nico Ghilardi, Daniel Cua, Calvin B. Williams, Melanie Gaignage, Reece Marillier, Jacques van Snick, William R. Drobyski

Blood (2016) 128 (16): 2068–2082.

https://doi.org/10.1182/blood-2016-02-698241

Published: 2016

Journal Articles

5 Year Results of BMT CTN 0201: Unrelated Donor Bone Marrow Is Associated with Better Psychological Well-Being and Less Burdensome Chronic Gvhd Symptoms Than Peripheral Blood

Stephanie J. Lee, MD MPH, Brent Logan, PhD, Peter Westervelt, MD PhD, Corey S Cutler, MD MPH, Ann E Woolfrey, MD, Shakila Khan, MD, Edmund K Waller, MD PhD, Richard T. Maziarz, MD, Juan Wu, Bronwen E. Shaw, MBChB, PhD MRCP, MRCPath, Dennis L. Confer, MD, Mary M. Horowitz, MD MS, Claudio Anasetti, MD

Blood (2015) 126 (23): 270.

https://doi.org/10.1182/blood.V126.23.270.270

Published: 2015

Journal Articles

Results of a Phase III Randomized, Multi-Center Study of Allogeneic Stem Cell Transplantation after High Versus Reduced Intensity Conditioning in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML): Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0901

Blood (2015) 126 (23): LBA-8.

https://doi.org/10.1182/blood.V126.23.LBA-8.LBA-8

Published: 2015

Journal Articles

Outcome of Patients 65 Years and Older with Myelodysplastic Syndrome (MDS) Receiving Allogeneic Hematopoietic Stem Cell Transplantation Compared to Patients 55-64 Years of Age

Ehab Atallah, MD, Mary M. Horowitz, MD MS, Brent Logan, PhD, Min Chen, MS, Michael J. Boo, JD, Corey S Cutler, MD MPH, Joachim Deeg, MD, James L. Gajewski, MD, Dennis L. Confer, MD, Stephanie Farnia, MPH, Peter Greenberg, MD, Erica Warlick, MD, Daniel Weisdorf, MD, J. Douglas Rizzo, MD

Blood (2015) 126 (23): 193.

https://doi.org/10.1182/blood.V126.23.193.193

Published: 2015

NARROW

Genotype, oxidase status, and preceding infection or autoinflammation do not affect allogeneic HCT outcomes for CGD

Impact of Public Reporting of Center-Specific Analysis Scores on Hematopoietic Cell Transplant Center Volumes

Development of a Validated Clinical Risk Score to Predict the Incidence of Acute Graft Versus Host Disease after Allogeneic Hematopoietic Cell Transplantation: A CIBMTR Analysis

Access: A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Patients with Hematologic Malignancies

Quality of Life in Patients Undergoing Double Umbilical Cord Blood Vs. Haploidentical Marrow Transplantation: A QOL Analysis Report of BMT CTN 1101

Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial

Impact of Cryopreservation of Donor Grafts on Outcomes of Allogeneic Hematopoietic Cell Transplant (HCT)

BMT CTN 1803: Haploidentical Natural Killer Cells (K-NK002) to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)

Expanded Comorbidity Definitions Improve Applicability of the Hematopoietic Stem Cell Transplantation-Comorbidity Index for Children, Adolescents, and Young Adults with Hematologic Malignancies Undergoing Allogeneic Stem Cell Transplantation

Bridging the Gap in Access to Transplant for Underserved Minority Patients Using Mismatched Unrelated Donors and Post-Transplant Cyclophosphamide: A National Marrow Donor Program/be the Match (NMDP/BTM) Initiative

Expanded Comorbidity Definitions Improve Application of the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) for Children and Young Adults with Non-Malignant Diseases Receiving Allogeneic Hematopoietic Cell Transplantation

Non-Infectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell Transplantation (HCT): A Center for International Blood and Marrow Transplant Research (CIBMTR) Study

A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplantation to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network Study 1102

BMT CTN 1803: Haploidentical Natural Killer Cells (CSTD002) to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)

The Hematopoietic Cell Transplant Comorbidity Index predicts survival after allogeneic transplant for nonmalignant diseases

Pain, Symptoms, AEs, and Recovery after Second Unrelated Donor Collection of Marrow/Peripheral Blood Stem Cells Are Similar to Those of the First Donation

Blockade of interleukin-27 signaling reduces GVHD in mice by augmenting Treg reconstitution and stabilizing Foxp3 expression

5 Year Results of BMT CTN 0201: Unrelated Donor Bone Marrow Is Associated with Better Psychological Well-Being and Less Burdensome Chronic Gvhd Symptoms Than Peripheral Blood

Results of a Phase III Randomized, Multi-Center Study of Allogeneic Stem Cell Transplantation after High Versus Reduced Intensity Conditioning in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML): Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0901

Outcome of Patients 65 Years and Older with Myelodysplastic Syndrome (MDS) Receiving Allogeneic Hematopoietic Stem Cell Transplantation Compared to Patients 55-64 Years of Age

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only